Abstract
Dear Editor, we read with interest the paper “COVID-19 Vaccine-Associated Subclinical Axillary Lymphadenopathy on Screening Mammogram” by Raj et al. (1Raj S Ogola G Han J. COVID-19 vaccine-associated subclinical axillary lymphadenopathy on screening mammogram.Acad Radiol. 2021; 6332 (Nov 17S1076-Online ahead of print): 00538-00539https://doi.org/10.1016/j.acra.2021.11.010Abstract Full Text Full Text PDF Scopus (0) Google Scholar) where the authors concluded that women who have received either mRNA COVID-19 vaccines may benefit from scheduling their screening mammogram at least 8 weeks after the vaccination. We concur that lymphadenopathy after COVID-19 vaccination might cause a problem in interpreting the mammogram and that having the mammogram before vaccination is useful. However, during the present pandemic, mass vaccination is needed, and it is often difficult to schedule a timely appointment for a mammogram. In cases in which it is not possible to have a prevaccination mammogram, a mammogram after vaccination is useful. Waiting for 10 weeks, similar to that recommended for nuclear imaging studies (2El-Sayed MS Wechie GN Low CS. et al.The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on (18)F-FD.Clin Med (Lond). 2021; 21: e633-e638Crossref Scopus (1) Google Scholar), might be appropriate. If the case is urgent, aiming at diagnostic not screening, the mammogram should be done without delay. 1a Substantial contributions to study conception and design. 1b. Substantial contributions to acquisition of data. 1c. Substantial contributions to analysis and interpretation of data. 2. Drafting the article or revising it critically for important intellectual content. 3. Final approval of the version of the article to be published. 1a Substantial contributions to study conception and design. 1b. Substantial contributions to acquisition of data. 1c. Substantial contributions to analysis and interpretation of data. 2. Drafting the article or revising it critically for important intellectual content. 3. Final approval of the version of the article to be published.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
